We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cells in Blood Manipulated and Sorted Via Ferrofluids

By LabMedica International staff writers
Posted on 16 Dec 2009
Print article
Technology that uses magnetizable liquids (ferrofluids) to rapidly manipulate and sort different cells in blood, could dramatically improve the speed and sensitivity of tests used to detect cancer biomarkers, blood disorders, viruses, and other diseases. The new method does not require attaching biomarkers, or labels to the cells thus eliminating labor-intensive preparation or postprocessing.

Ferrofluids comprise magnetic nanoparticles suspended throughout a liquid carrier. A biocompatible ferrofluid--one with the right pH level and salinity so that human cells can survive in it for several hours—was developed together with a device that has integrated electrodes that generate a magnetic field pattern.

The magnetic field attracts the nanoparticles in the ferrofluid, effectively pushing and shuffling the much larger, nonmagnetic cells along specific channels. Depending on the frequency of the magnetic field applied different types of cells are manipulated and sorted according to their size, elasticity, and shape.

Being able to effectively sort and move cells with this technique could allow for much greater efficiency in disease detection. Many of today's tests require hours or even days to complete, because the concentration of diseased cells in a blood sample may be so low that it takes a long time for them to randomly bump into the sensors. For example, in early-stage cancer there could be one tumor cell for every billion healthy cells, making the cells extremely difficult to detect.

The new technology was developed by a team of scientists led by Hur Koser, associate professor at the Yale School of Engineering & Applied Science (New Haven, CT, USA) together with colleagues at the Deutsches Elektronen-Synchrotron (DESY; Hamburg, Germany) and University of Georgia (Athens, GA, USA). The findings were published in the December 7, 2009 online edition of the Proceedings of the National [U.S.] Academy of Sciences (PNAS).

Related Links:
Yale School of Engineering & Applied Science
Deutsches Elektronen-Synchrotron
University of Georgia

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.